Introduction
Myocardial infarction (MI) results from insufficient blood supply to the heart and causes substantial death of cardiac cells and scar formation. 1, 2 Cardiac tissue hypoxia in the setting of MI triggers endothelial-tomesenchymal transition (EndMT), which further contributes to cardiac dysfunction by increasing cardiac fibroblastic content and limiting cardiac vasculature. 3 MI is also associated with reduced myocardial capillary flow reserve and capillary density, resulting in impaired tissue perfusion as well as augmented cellular injury and scar formation. 4, 5 Cardiac injury is accompanied by dynamic changes in the expression of microRNAs (miRNAs or miRs), which are endogenous, small single strand, non-coding RNAs that down-regulate target genes. 6, 7 MiRs are increasingly recognized as important regulators of cardiac function and disease. 8, 9 The b-adrenergic receptor antagonist (b-blocker) carvedilol (Carv) promotes cardioprotection via b-arrestin-biased agonism of b-adrenergic receptor (bAR). [10] [11] [12] [13] MiR-532-5p (hereinafter referred to as miR-532) is one of the miRs that we found to be activated by Carv in the heart. 14 MiR-532 expression is dysregulated in a variety of conditions. For example, miR-532 is up-regulated in myoblasts from muscle and type 2 diabetes, 17 or human endothelial progenitor cells under hypoxic conditions, 18 while it is down-regulated in plasma from patients with chronic obstructive pulmonary disease 19 or fractures. 20 Although miR-532 has been implicated in the pathophysiology of certain cancers [21] [22] [23] and as a mediator of anti-viral host defence, 24 there is no evidence that miR-532 plays a functional role in the heart. Prss23 is a serine protease and highly conserved in vertebrates. In aortic endothelial cells in vitro and in cardiac valve formation during zebrafish development, prss23 has been shown to induce Snail-mediated EndMT signalling, 25 a maladaptive process that was reported to inhibit cardiac neovascularization in pressure over-load and ischemia/reperfusion (I/R) mouse models. 26, 27 Notably, prss23 was significantly up-regulated in cancer stem cells 28 and has been associated with tumour progression in various types of cancers 29, 30 as well as renal fibrosis. 31 Interestingly, we found that prss23 was down-regulated in mouse hearts upon Carv stimulation. 32 However, whether this gene is functionally regulated by the Carv-responsive miR-532 and contributes to cardiac pathology is unknown.
Here, we show that knockdown of miR-532 alters the pathological responses of the heart in MI, and that miR-532 acts as a gatekeeper of cardiac vascularization by repressing a known EndMT initiator prss23. Therefore, miR-532 may represent a novel therapeutic target for combating ischemic heart injury.
Methods

Animal study
Eight to 12-week-old C57BL/6 wild-type (WT) mice were used for this study. Research with animals carried out for this study was performed according to approved protocols and animal welfare regulations of Augusta University's Institutional IACUC Committees. All animal procedures were performed in accordance with NIH guidelines. Mice were euthanized by thoracotomy under 1-4% inhalant isoflurane.
Histology and immunohistochemistry
The hearts were harvested and weighed before undergoing gross anatomical inspection. Morphometric analysis of the heart size was performed as previously published. 33 Histo-pathological analysis of the cardiac tissues, including fibrosis (Masson's trichrome staining), was performed using standard procedures as previously described. 34, 35 For gross histological examination, sections were stained with haematoxylin and eosin (H and E). Myocardial sections were also stained for TUNEL to measure apoptosis using In Situ Cell Death Detection Kits (Roche) according to the manufacturer's instructions. The following anti-bodies were used to mark the cardiac endothelial cells (CECs) and cardiomyocytes (CMs), respectively: CD31, rabbit polyclonal (ab28364, Abcam), and Troponin I (TnI), rabbit polyclonal (sc-15368, Santa Cruz). To identify all active phases of cell cycle (G1, S, G2, and M) and mitosis, we used Ki67, rabbit polyclonal (ab15580, Abcam); and phospho-histone H3 (PH3), rabbit polyclonal (ab5176, Abcam) anti-bodies, respectively. We also used collagen type 1 a1 (COL1A1), mouse monoclonal (sc-293182, Santa Cruz), and a-smooth muscle actin (a-SMA), mouse monoclonal (ab7817, Abcam) anti-bodies to visualize myofibroblasts.
Statistical analysis
Data are expressed as mean ± SEM from at least three independent experiments with different biological samples per group. Statistical significance was determined using two-way ANOVA for two variables, one-way ANOVA with Bonferroni correction for multiple comparisons, or Student unpaired t-tests (GraphPad Prism version 5). A P value < 0.05 was considered statistically significant. Other methods are provided in Supplementary material online.
Results
In vivo knockdown of miR-532 augments post-MI cardiac dysfunction and remodelling
To investigate the role of miR-532 in experimental MI, we intramyocardially injected locked nucleic acid (LNA) TM -anti-miR-532 into WT mice immediately after left anterior descending (LAD) occlusion or sham surgery. First, we demonstrated efficacy of the anti-miR-532 by showing that the level of miR-532 was reduced (by 55%) after 7 days compared with anti-miR controls in both the sham and MI groups. We also observed down-regulation of miR-532 in the hearts of WT mice subjected to 1 week of MI ( Figure 1A) . We further showed that the hearts of anti-miR-532-injected mice at baseline were functionally normal (Figure 1B-F and see Supplementary material online, Table S1-S3). These findings suggest that miR-532 does not affect basal cardiac function in the absence of a pathological insult. Despite the normal phenotype at baseline, knockdown of miR-532 resulted in augmented cardiac dysfunction (as evidenced by significantly decreased EF, FS, and LVAWs as well as increased LVIDs and LVIDd), and increased ratios of HW/BW and LVW/BW at 3 days ( Figure  1B Table S3 ) after MI, when compared with controls. However, we did not observe a significant difference in mortality between anti-miR-532-injected mice and anti-miR controls following ligation of the LAD (data not shown).
We also found that anti-miR-532-injected hearts exhibited increased disorganized structure as well as loss of normal architecture and cellular integrity at 7 days post-MI as compared with anti-miR control hearts (Figure 2A) , which is consistent with our biochemical data showing that knockdown of miR-532 led to increased mRNA levels of fetal genes and pro-inflammatory TNF-a compared with anti-miR controls ( Figure 2B , C and see Supplementary material online, Figure S1A -C). To further assess the consequence of miR-532 knockdown following MI, we examined fibrosis by Masson's trichrome staining and by quantifying fibrotic gene expression. At 7 days post-MI, treatment with anti-miR-532 resulted in a much greater degree of fibrosis ( Figure 2D, E) , and increased mRNA levels of fibrotic Col3a1 ( Figure 2F ), as compared with anti-miR controls.
We next demonstrated that anti-miR-532-injected hearts had higher numbers of TUNEL-positive cells in the heart sections at 7 days post-MI as compared with anti-miR controls ( Figure 3A, B) . This is consistent with our biochemical data showing increased mRNA levels of pro-apoptotic Bax following knockdown of miR-532 compared with controls ( Figure  3C) . Collectively, these results suggest that knockdown of miR-532 resulted in diverse pathological abnormalities during post-MI cardiac structural/functional remodelling.
In vivo knockdown of miR-532 reduces CEC proliferation and cardiac vascularization after MI
To further assess the effects of anti-miR-532, we examined cell proliferation post-MI using immunostaining for Ki-67 and phosphorylated
histone H3 (PH3), which mark active phases of the cell cycle and mitosis, respectively. We detected reductions in both markers in hearts injected with anti-miR-532 compared with controls (see Supplementary material online, Figure S2A , B and Figure 3D , E). This is consistent with our biochemical data showing that anti-miR-532-injected hearts had decreased mRNA levels of S-phase marker PCNA and mitosis marker Aurora B compared with anti-miR controls (see Supplementary material online, Figure  S2C and Figure 3F ). To determine which cell types underwent less proliferation in anti-miR-532-injected hearts, we co-labelled heart sections to detect Ki-67 along with the CM marker TnI or the endothelial cell (EC) marker CD31. We found that knockdown of miR-532 resulted in lower numbers of Ki67-positive CECs, but not CMs, at 7 days after MI compared with controls (see Supplementary material online, Figure  S2D -F). We next examined the expression of miR-532 in different myocardial cells. The expression of miR-532 was significantly higher in CECs than other myocardial cells and was selectively down-regulated in CECs isolated from ischemic myocardium at 1 week post-MI ( Figure 4A ). Both a previous cellular uptake study showing that injections of low doses of anti-miRs (such as 0.5 mg/kg used in our study) repressed miRs mainly in fractionated ECs in the heart 36 and this miR-532 expression data in myocardial cells ( Figure 4A ) correlated with our cell-type specific effect of miR-532 knockdown (see Supplementary material online, Figure S2D -F).
Because we detected less CEC proliferation in anti-miR-532-injected hearts, we next tested the hypothesis that impaired CEC proliferation may contribute to increased fibrosis and cell death observed in anti-miR-532-injected hearts. Notably, both capillary density and the expression of EC markers were significantly reduced in anti-miR-532-injected hearts compared with anti-miR controls ( Figure 4B -E), suggesting that miR-532 protects the myocardium in part through neovascularization after MI.
MiR-532 regulates a positive regulator of EndMT, prss23
In order to identify candidate miR-532 target genes that regulate cardiac pathology and impair CEC responses, we first used bioinformatic miRNA target prediction tools [37] [38] [39] and detected a substantial number of genes with putative binding sites for miR-532. Although functional miR binding sequences are often located in the 3 0 -untranslated region (3 0 -UTR) of target mRNA, it has been reported that the miR target can also occur with the 5 0 -UTR 40 or coding region. 41 By focusing our attention on predicted target genes that were also down-regulated in the mouse heart upon Carv stimulation in our previous study, 32 we identified prss23 as a gene of interest among hundreds of possible targets. The rationale to focus on prss23 is that Carv may inhibit the target by up-regulating miR-532. The sequence of miR-532 is conserved between mouse and human. Human prss23 has two miR-532 binding sites (one strong site with 7 bp seed length and one weak site with 6 bp seed length based on miRanda) and one strong binding site with 7 bp seed length (based on 
TargetScan) in its 3
0 -UTR. Although mouse prss23 3 0 UTR does not have the miR-532 binding site, mouse prss23 possesses a strong miR-532 binding site with 7 bp seed length in its 5 0 -UTR (based on miRWalk and RNAhybrid), suggesting evolutionary conservation of miR-532's regulation of prss23 and their roles between mouse and human despite different target locations. This idea is supported by a previous finding demonstrating that the function of prss23 in valvulogenesis is evolutionarily conserved.
25
Prss23 is a serine protease that was reported to regulate EndMT in aortic ECs in vitro and cardiac valve formation during zebrafish development in vivo via inducing Snail1-mediated EndMT signalling. 25 To validate prss23
as a novel functional target of miR-532 in CECs and hearts, we first measured the mRNA and protein levels of prss23, as well as downstream Snail1 protein levels, in anti-miR-532-injected hearts. We showed that anti-miR-532-injected mouse hearts exhibited significant up-regulation of mRNA and protein levels of prss23 both at baseline and 7 days post-MI compared with controls ( Figure 5A-C) , suggesting that miR-532 promotes the degradation of prss23 mRNA. The protein level of Snail1, which is activated by prss23 in EndMT, 25 was also increased in anti-miR-532 MI group compared with anti-miR controls ( Figure 5B, C) . We also found that runx3 was up-regulated in anti-miR-532-injected hearts both at baseline and 7 days post-MI compared with controls (see Supplementary material online, Figure S3A ). Interestingly, runx3 has been identified as a direct target of miR-532 in gastric cancer, 23 and it is also known to promote
EndMT by inducing Slug. 42 Importantly, we demonstrated that miR-532
expression is down-regulated in the hearts of WT mice subjected to 3, 5, The role of miR-532 in acute myocardial infarction and 7 days of MI compared with controls (see Supplementary material online, Figure S3B ), while cardiac expression of prss23 was concomitantly up-regulated (see Supplementary material online, Figure S3C) . Interestingly, the expression of prss23 in CECs was significantly lower than other myocardial cells and selectively up-regulated in CECs isolated from ischemic myocardium at 7 days post-MI ( Figure 5D ), which is inversely associated with the expression of miR-532 ( Figure 4A) .
To test whether prss23 is a direct target of miR-532 repression, we co-transfected CECs with constitutively active luciferase reporter constructs containing 3 0 UTR of prss23 ( Figure 5E ) and miR-532 mimic. We observed repression of luciferase activity by miR-532 for the prss23-3 0 UTR reporter. Mutation of seed binding sites for miR-532 made the reporter insensitive to miR-532 over-expression ( Figure 5F ), indicating the specific dependence of target 3 0 -UTR on miR-532. Together with our previous studies demonstrating that Carv decreased the expression of prss23 concordant with up-regulation of miR-532, 14,32 our current results showing an inverse relationship during MI strongly suggest that prss23 is an important direct target of miR-532 in the heart.
MiR-532 functions as a protective miR by repressing a positive EndMT regulator, prss23 in CECs
Because our data suggest that prss23, a key promoter of EndMT is a novel direct target of miR-532, we hypothesized that miR-532 may inhibit EndMT, subsequently decreasing cardiac fibroblastic content and
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promoting cardiac vascularization. To examine the potential role of miR-532 in EndMT, we first performed double staining for COL1A1 or a-SMA and CD31 in heart sections of anti-miR-532-injected mice and anti-miR controls. We observed that anti-miR-532-injected mouse hearts exhibited an increase of both COL1A1/CD31 and a-SMA/CD31 double-positive cells both at baseline and 7 days post-MI compared with controls (see Supplementary material online, Figure S4) . Combined with Figures 2D-F and 4B-E showing that anti-miR-532-injected hearts had increased cardiac fibroblastic content and deceased cardiac vascularization, our data suggest that miR-532 inhibits EC conversion into fibroblast-like cells (i.e. EndMT) in the heart.
It is known that prss23 modulates Snail1 transcription to promote TGF-b2-mediated EndMT initiation in human aortic ECs, 25 and that only
ECs and macrophages uptake acetylated-LDL (ac-LDL). 43 To determine the importance of miR-532 for TGF-b2-mediated EndMT in CECs, we exposed MCECs to TGF-b2 for 7 days and then labelled them with DilAc-LDL. Knockdown of miR-532 in MCECs decreased Dil-Ac-LDL uptake (see Supplementary material online, Figure S5A , B), indicating a loss of endothelial functionality. Moreover, knockdown of miR-532 resulted in decreased expression of VWF and CD31 in the absence and presence of TGF-b2 compared with anti-miR controls (see Supplementary material online, Figures S5C and S6B, C) , while expression of Col3a1, Snail1, and a-SMA was up-regulated in the presence of TGF-b2 (see Supplementary material online, Figures S5D and S6A, B, and D) . These results suggest that knockdown of miR-532 in CECs promotes transition to a fibroblast-like phenotype via EndMT.
To begin to address the therapeutic potential of miR-532, we next investigated whether miR-532 over-expression is beneficial in preventing 
EndMT and induction of prss23 in CECs. Over-expression of miR-532 in MCECs increased Dil-Ac-LDL uptake in the presence of TGF-b2 ( Figure  6A, B) , indicating a gain of endothelial functionality. Moreover, over-expression of miR-532 resulted in increased expression of VWF in the absence or presence of TGF-b2 compared with miR mimic controls, while expression of Col3a1 and prss23 was down-regulated in the presence of TGF-b2 ( Figure 6C-E) . We next determined if the target of miR-532, prss23 regulates EndMT in CECs. Loss-of-function approaches demonstrated that compared with controls, knockdown of prss23 increased DilAc-LDL uptake (see Supplementary material online, Figure S7A and Figure  7A , B), expression of VWF (see Supplementary material online, Figure S7C ) and CD31 ( Figure 7C, D) in response to TGF-b2, and decreased expression of Snail1, Col3a1, and a-SMA in the presence of TGF-b2 (see Supplementary material online, Figure S7D , E, and Figure 7C and E). Our results suggest that prss23 is sufficient to promote TGF-b2-mediated EndMT in CECs. Finally, to establish a functional linkage between miR-532, prss23 expression, and EndMT, we applied a siRNA/anti-miR-based rescue strategy to validate the functional relevance of the novel miR-532 target. Consistent with our earlier observations (see Supplementary material online, Figure S5A-D) , anti-miR-532 treatment promoted EndMT, which was blocked by siRNA against prss23 ( Figure 7A -E and see Supplementary material online, Figure S7A -E). Taken together, our CEC data support the in vivo evidence that miR-532 exerts cardioprotective effects in part through functional repression of a positive regulator of EndMT, prss23.
Discussion
Here, we identify miR-532 as a stress-responsive protector against EndMT both in vivo and in vitro. Knockdown of miR-532 in the heart augments injury in the setting of MI, as evidenced by increased cardiac cell death and fibrosis, decreased CEC proliferation and cardiac vascularization, and impairment of ventricular function. Mechanistically, we determined that miR-532 targets an EndMT initiator prss23 to, at least in part, elicit its protective effects. In vitro, CECs deficient in miR-532 exhibit increased sensitivity to TGF-b2-mediated EndMT, while CECs over-expressing miR-532 display decreased EndMT.
EndMT is a key mechanism by which cardiac fibroblasts increase production of extracellular matrix proteins and is characterized by loss of cell junctions and CD31 expression as well as up-regulated expression of mesenchymal markers such as a-SMA. 43 EndMT has been shown to significantly contribute to cardiac fibrosis and heart failure in pressureinduced cardiac damage, 26, 44 while the opposite process of mesenchymal-to-endothelial transition (MEndT) was shown to contribute to cardiac neovascularization in cardiac I/R injury. 27 Although miR200b was reported to mediate EndMT in diabetic cardiomyopathy, 45 a pathophysiologic role of other miRs in regulating EndMT in the heart has not been previously demonstrated. In the current study, we show that miR-532 reduces expression of Snail1, Col3a1, and a-SMA in the heart and CEC, while increasing expression of Pecam1, VWF, and CD31, confirming a role of this miR in EndMT. Our COL1A1 or a-SMA/CD31 double staining data also support that miR-532 inhibits CEC conversion into myofibroblasts in the heart. We further show that miR-532 confers cardioprotective effects against MI in part by directly repressing a key EndMT initiator, prss23. Prss23 is essential for the initiation of EndMT via Snail1 during cardiac valvulogenesis, and this prss23-mediated mechanism is evolutionally conserved. 25 Whether miR-532 regulates
EndMT via additional regulatory mechanisms in the context of MI is unknown and beyond the scope of the current investigation. We previously showed that miR-532 is activated by Carv, 14 which is a b-arrestin-biased ligand for b 2 AR. 12 Our data also suggest that miR-532 is post-transcriptionally activated by b-arrestin-mediated b 2 AR signalling pathways (data not shown), which have recently been identified to promote cardioprotective effects 13, 46 ( Figure 8A-C) . Together with the results presented here ( Figure 8D ), we postulate that b-arrestin-biased b 2 AR regulatory mechanism of miR biogenesis may result in beneficial adaptive remodelling following MI. This hypothesis is further supported by the observation that other Carv/b-arrestin1-regulatable miRs that we identified 14 are cardioprotective in vivo after I/R injury or MI. 33, [47] [48] [49] Interestingly, two other studies linking Carv treatment to up-regulation of cardioprotective miRs have been also reported in MI. 50, 51 Basal expression of the cardioprotective miR-133 52, 53 in myocardial tissue was significantly up-regulated by Carv treatment, and up-regulation of miR-133 mediated the anti-apoptotic action of Carv in isolated CMs. 50 The up-regulation of miR-29b, another cardioprotective miR, 54 was also shown to contribute to the effects of Carv to attenuate post-MI fibrosis. 51 Collectively, these studies support the concept that the cardioprotective actions of Carv are associated with increased levels of cardioprotective miRs. Future studies are needed to fully elucidate the possible over-lapping/compensatory effects of known Carv-responsive miRs and their underlying mechanisms of action. Prss23 is expressed in multiple organs in developing fetuses and adults, and is involved in tissue remodelling in the mouse ovary 55 and estrogen-dependent proliferation in breast cancer. 30 Interestingly, its expression is relatively high in the human fetal heart and up-regulated during mouse cardiac development. Prss23 has been reported to mediate EndMT signalling in aortic ECs during cardiac valvulogenesis. 25 In this study, we demonstrate for the first time that prss23 is a functional and direct CEC target of miR-532. Prss23 expression was reported to be upregulated in cancer stem cells 28 and has been associated with tumour progression in various types of cancers 29, 30 as well as renal fibrosis. 31 Our findings of up-regulation of prss23 during MI (see Supplementary material online, Figure S3C ) further support that inhibition of this gene could be therapeutically beneficial for cardiac disease although the role of prss23 in vivo needs to be determined. Given our data that this detrimental gene is a functional and direct CEC target of miR-532, and that there is an inverse correlation between miR-532 and prss23 during MI, up-regulating miR-532 (via Carv or miR-532 over-expression) could be a particularly attractive adjunctive approach to limiting peri-infarct damage and promoting recovery post-MI. However, these studies need to be done before considering this miR as a therapeutic option.
In conclusion, our results using loss-of-function approaches demonstrate for the first time that miR-532 protects the heart against MI in part by blunting EndMT in response to injury through its direct repression of prss23 ( Figure 8D) . We identified miR-532 as a critical regulator of CEC proliferation and cardiac vascularity after MI. We found miR-532 to be highly expressed in fractionated CECs and to be down-regulated after ischemic injury. However, miR-532 is also expressed in other myocardial cells. This finding, coupled with the excessive post-MI cardiac remodelling resulting from knockdown of miR-532, suggest a possible EC- 
